Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Verapamil and breast-feeding.

M R Miller, R Withers, R Bhamra

    European Journal of Clinical Pharmacology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Polyaromatic hydrocarbons in pollution: a heart-breaking matter.

    The Journal of physiology·2019
    Same author

    Cardiovascular benefits of reducing personal exposure to traffic-related noise and particulate air pollution: A randomized crossover study in the Beijing subway system.

    Indoor air·2018
    Same author

    Association of size-fractionated indoor particulate matter and black carbon with heart rate variability in healthy elderly women in Beijing.

    Indoor air·2018
    Same author

    On the origins and genetic diversity of South American chickens: one step closer.

    Animal genetics·2017
    Same author

    Whole-eye transplantation: a look into the past and vision for the future.

    Eye (London, England)·2016
    Same author

    Cohort Profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) Cohort Study.

    International journal of epidemiology·2016

    Maternal verapamil therapy is generally safe for infants. Verapamil levels in breast milk were lower than in maternal plasma, and undetectable in infant plasma, indicating no significant infant exposure.

    Area of Science:

    • Pharmacology
    • Neonatal Medicine
    • Lactation Studies

    Background:

    • Verapamil is a commonly prescribed calcium channel blocker for various cardiovascular conditions.
    • Assessing the safety of maternal medication transfer to infants via breast milk is crucial for breastfeeding mothers.

    Purpose of the Study:

    • To quantify verapamil and its metabolite, norverapamil, concentrations in maternal plasma and breast milk.
    • To determine infant exposure levels to verapamil during breastfeeding.
    • To evaluate the safety of maternal verapamil therapy for nursing infants.

    Main Methods:

    • Pharmacokinetic analysis of verapamil and norverapamil.
    • Measurement of drug concentrations in maternal plasma and breast milk samples.
    • Analysis of drug concentrations in infant plasma samples.

    Related Experiment Videos

    Main Results:

    • Verapamil concentrations in breast milk averaged 64% of maternal plasma concentrations.
    • No detectable levels of verapamil or norverapamil were found in the infant's plasma.
    • Norverapamil concentrations were not specified but implied to be undetectable or negligible.

    Conclusions:

    • Maternal verapamil therapy at the studied dosage (120 mg three times daily) does not appear to pose a significant hazard to the suckling infant.
    • The low transfer of verapamil into breast milk and its absence in infant plasma suggest minimal infant exposure.
    • Further studies may be warranted to confirm findings across different dosages and patient populations.